Real-World Effectiveness of Boosting Against Omicron Hospitalization in Older Adults, Stratified by Frailty
Authors:
- Liang En WeeLWLiang En Wee
- Enoch Xue Heng LoyELEnoch Xue Heng Loy
- Jue Tao LimJLJue Tao Lim
- Wei Hao KwokWKWei Hao Kwok
- Calvin ChiewCCCalvin Chiew
- Christopher LienCLChristopher Lien
- Barbara Helen RosarioBRBarbara Helen Rosario
- Ian Yi Onn LeongILIan Yi Onn Leong
- Reshma Aziz MerchantRMReshma Aziz Merchant
- David Chien Boon LyeDLDavid Chien Boon Lye
- Kelvin Bryan TanKTKelvin Bryan Tan
Open Access
Abstract
Background/Objectives: Older adults with frailty are at-risk of worse outcomes following respiratory-viral-infections such as COVID-19. Data on effectiveness of vaccination/boosting in frail older adults during Omicron is lacking. Methods: National healthcare-claims data and COVID-19 registries were utilized to enroll a cohort of older Singaporeans (≥60 years) as of 1 January 2022, divided into low/intermediate/high-risk for frailty; matching weights were utilized to adjust for sociodemographic differences/vaccination uptake at enrolment across frailty categories. Competing-risk-regression (Fine-Gray) taking death as a competing risk, with matching weights applied, was utilized to compare risks of COVID-19-related hospitalizations and severe COVID-19 across frailty levels (low/intermediate/high-risk), with estimates stratified by booster status. Individuals were followed up until study end-date (20 December 2023). Results: 874,160 older adults were included during Omicron-predominant transmission; ~10% had intermediate/high-frailty-risk. Risk of hospitalization/severe COVID-19 was elevated in those with intermediate/high-frailty-risk up to XBB/JN.1 transmission. Boosting was associated with decreased risk of COVID-19-related hospitalization across all frailty categories in infection-naïve individuals. However, in infection-naïve older adults with high-frailty-risk, while receipt of first boosters was associated with lower risk of COVID-19-hospitalization/severe COVID-19, additional booster doses did not reduce risk. In reinfected older adults, first boosters were still associated with lower hospitalization risk (adjusted-hazards-ratio, aHR = 0.55, 95% CI = 0.33–0.92) among the non-frail, but not in the intermediate/high-frailty-risk minority. Conclusions: First boosters were associated with reduced adverse COVID-19 outcomes across all frailty categories in infection-naïve older adults during Omicron. However, in the high-frailty minority, boosting did not additionally reduce risk in reinfected individuals with hybrid immunity, and beyond the first booster for infection-naïve individuals.Keywords
This publication has 55 references indexed in Scilit:
- Impact of sarcopenia and obesity on mortality in older adults with SARS-CoV-2 infection: automated deep learning body composition analysis in the NAPKON-SUEP cohortInfection, 2025
- Preparing for future pandemics: frailty associates with mortality in hospitalised older people during the entire COVID-19 pandemic, a Dutch multicentre cohort studyEuropean Geriatric Medicine, 2024
- Multimorbidity and frailty are associated with poorer SARS-CoV-2-related outcomes: systematic review of population-based studiesAging Clinical and Experimental Research, 2024
- Vaccination and the risk of post-acute sequelae after COVID-19 in the Omicron-predominant periodClinical Microbiology and Infection, 2024
- Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US AdultsJAMA Network Open, 2023
- Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmissionClinical Microbiology and Infection, 2023
- The effects of obesity and metabolic abnormalities on severe COVID-19-related outcomes after vaccination: A population-based studyCell Metabolism, 2023
- Frailty Reduces Vaccine Effectiveness Against SARS-CoV-2 Infection: A Test-Negative Case Control Study Using National VA DataThe Journal of nutrition, health and aging, 2023
- Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly vaccinated Asian setting: a test-negative design studyClinical Microbiology and Infection, 2022
- Proportion of asymptomatic infection and nonsevere disease caused by SARS‐CoV‐2 Omicron variant: A systematic review and analysisJournal of Medical Virology, 2022